THE END OF STATINS? Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study. “Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial, an early but encouraging test of whether a one-time treatment may one day help people seeking to lower their LDL, or ‘bad,’ cholesterol.”